Also found in: Wikipedia.


Gynecology A member of a new class of Estrophasic OCs that release gradually increasing amounts of estrogen–ethinyl estradiol, and a constant low dose of progestin–norethindrone acetate. See Oral contraceptive.
Mentioned in ?
References in periodicals archive ?
TABLE FDA-approved estrogen-progestin contraceptives for the treatment of acne Brand name Generic name Estrostep Norethindrone acetate-ethinyl estradiol plus ferrous fumarate Ortho Tri-Cyclen Norgestimate-ethinyl estradiol Yaz Drospirenone-ethinyl estradiol BeYaz Drospirenone-ethinyl estradiol plus levomefolate
OCPs with FDA approval for the treatment of acne include Estrostep Fe (norethindrone/ethinyl estradiol [EE]), Ortho Tricyclen (norgestimate/EE), and Yasmin and Beyaz (drospirenone/EE).
Four are approved for this indication: Ortho Tri-Cyclen, Estrostep, YAZ, and Beyaz.
But since at least 1995, research has shown that these newer pills double the blood-clot risk of earlier, "second generation" pills, such as TriNessa and Estrostep.
Ortho Tri-Cyclen (norgestimate/ethinyl estradiol) and Estrostep (norethindrone acetate/ethinyl estradiol) have been approved by the Food and Drug Administration for the treatment of acne.
The group counts contraceptives Ovcon and Estrostep among its brands.
The group counts contraceptives Ovcon and Estrostep among its brands as well as combination hormone therapy treatment femhrt and Sarafem.
9 million, with strong growth in sales of oral contraceptive profits via Ovcon and Estrostep.
Products which performed strongly during the period included women's healthcare brands Ovcon, Estrostep and Femhrt.
Revenues were boosted by the purchase of two oral contraceptive pills - Loestrin and Estrostep - from Pfizer in March and the hormone replacement drug Femhrt a month later.